Form 8-K

8-K — SPLASH BEVERAGE GROUP, INC.

Accession: 0001731122-26-000982

Filed: 2026-07-29

Period: 2026-07-28

CIK: 0001553788

SIC: 2080 (BEVERAGES)

Item: Entry into a Material Definitive Agreement

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7811_8-k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (e7811_ex10-1.htm)

EX-99.1 — EXHIBIT 99.1 (e7811_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7811_8-k.htm · Sequence: 1

false

0001553788

2026-07-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 28, 2026

SPLASH BEVERAGE GROUP, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-40471

34-1720075

(State or other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1112 N. Flagler Drive

Fort Lauderdale, Florida

33304

(Address of principal executive offices)

(Zip Code)

Registrant’s

telephone number, including area code: (954) 648-7238

(Former

name or former address, if changed since last report.): n/a

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

SBEV

NYSE American LLC

Item 1.01 Entry into a Material Definitive Agreement

On July 28, 2026, Splash Beverage Group, Inc. (the

“Company”) and Argent BioPharma Limited (ASX/LSE: RGT) (the “Licensor”) entered into an addendum (the “Addendum”)

to that certain exclusive global license agreement for CannEpil®, dated July 6, 2026 (the “License Agreement”). Pursuant

to the Addendum, the License Agreement was amended to: (i) expand the field of use under the License Agreement to include veterinary applications;

(ii) provide for an amended royalty rate payable to the Licensor equal to 10% of Net Revenue (as defined in the License Agreement) attributable

to veterinary applications and 15% of Net Revenue attributable to human applications; and (iii) extend various deadlines provided for

under the License Agreement. The Company previously disclosed the License Agreement and filed a copy thereof as Exhibit 10.1 in the Company’s

Current Report on Form 8-K filed on July 6, 2026.

The foregoing description of the Addendum does not

purport to be complete and is qualified in its entirety by reference to the full text of the Addendum, a copy of which is filed as Exhibit

10.1 and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure

On July 29, 2026, Splash Beverage Group, Inc. issued

a press release announcing that it has expanded its exclusive global license for CannEpil® with Argent BioPharma Limited (ASX/LSE:

RGT) to include veterinary applications. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.

The information in this Item 7.01 (including Exhibit

99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)

or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of

the Company under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

Description

10.1

Addendum No. 1 to the Exclusive License Agreement, dated July 29, 2026, by and between the Company and Argent BioPharma Limited

99.1

Press Release dated July 29,

2026

104

Cover Page Interactive Data File (embedded within the Inline

XBRL document)

SIGNATURES

Pursuant to the requirements of

the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

SPLASH BEVERAGE GROUP, INC.

Date: July 29, 2026

By:

/s/ Brady Cobb

Name:

Brady Cobb

Title:

Interim Chief Executive Officer

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: e7811_ex10-1.htm · Sequence: 2

EXHIBIT 10.1

ADDENDUM NO. 1

TO THE EXCLUSIVE LICENSE AGREEMENT

This Addendum No. 1 (this “Addendum”)

is entered into as of July 28, 2026 (the “Addendum Effective Date”), by and between Argent Biopharma Limited

(“RGT”) and Splash Beverage Group, Inc. (“SBEV”), and amends that certain Exclusive

License Agreement dated July 6, 2026 (the “Agreement”). Capitalized terms used but not defined herein shall

have the meanings ascribed to them in the Agreement.

RECITALS

WHEREAS, the Parties desire

to expand the Field under the Agreement to include both human and veterinary purposes;

WHEREAS, SBEV intends to

enter into a Development and Collaboration Agreement with Lupvindol UK Limited (the “Collaboration Agreement”)

for the purpose of advancing the Licensed Product as an Investigational Veterinary Product through the FDA Center for Veterinary Medicine

INAD and Conditional Approval pathway;

WHEREAS, in consideration

of the expanded Field and the Collaboration Agreement, the Parties desire to establish differentiated royalty rates for the Human Field

and the Veterinary Field (as defined below);

WHEREAS, the Parties desire

to revise certain delivery and execution deadlines under the Agreement; and

WHEREAS, the Parties desire

to amend the Agreement to reflect such changes.

NOW, THEREFORE, in consideration of the mutual

covenants and agreements set forth herein, the Parties agree as follows:

1. Amendment

to Definition of “Field” (Section 1.9). Section 1.9 of the Agreement is hereby deleted in its entirety and replaced with

the following:

“1.9. ‘Field’

means: (a) the treatment, prevention, management, or amelioration of drug-resistant epilepsy, refractory epilepsy, seizure disorders,

and all related neurological conditions in humans, including as an adjunctive or add-on therapy (the ‘Human Field’);

and (b) veterinary purposes, including the treatment, prevention, management, or amelioration of diseases, conditions, or disorders in

non-human animals, including as an adjunctive or add-on therapy (the ‘Veterinary Field’).”

2. Amendment

to Running Royalty (Section 4.2). Section 4.2 of the Agreement is hereby deleted in its entirety and replaced with the following:

“4.2. Running Royalty. SBEV shall pay

to RGT a royalty (the ‘Royalty’) calculated as follows: (a) fifteen percent (15%) of Net Revenue attributable

to the Human Field; and (b) ten percent (10%) of Net Revenue attributable to the Veterinary Field. The Royalty shall be payable for so

long as SBEV or any Affiliate or sublicensee sells the Licensed Product in the Territory and the longer of: (i) ten (10) years following

the First Commercial Sale in each country; or (ii) the expiration of the last-to-expire Patent claiming the Licensed Product in each country.

For sales by sublicensees, the Royalty shall be calculated on the Net Revenue received by SBEV from such sublicensee.”

3. Amendment

to Product Specifications (Schedule A). The reference in Schedule A to delivery of Product Specifications “within 30 days of

the Effective Date” is hereby deleted and replaced with “within sixty (60) days after receipt by SBEV of the Data Package.”

4. Data

Package (Section 5.6(a)). For the avoidance of doubt, the deadline for RGT to deliver the Data Package under Section 5.6(a) of the

Agreement (sixty (60) days following the Effective Date) remains unchanged.

5. Amendment

to Development Plan (Section 5.2). The first sentence of Section 5.2 of the Agreement is hereby amended by deleting “Within

ninety (90) days following the Effective Date” and replacing it with “Within one hundred twenty (120) days after the date

of receipt by SBEV of the Data Package”.

6. Amendment

to Safety Data Exchange Agreement (Section 5.7(a)). The reference in Section 5.7(a) of the Agreement to execution of the Safety Data

Exchange Agreement “within ninety (90) days after the Effective Date” is hereby deleted and replaced with “within one

hundred twenty (120) days after the date of receipt by SBEV of the Data Package”.

7. Amendment

to Supply Agreement and Quality Agreement (Section 5.9). The reference in Section 5.9(a) of the Agreement to execution of the supply

agreement and quality agreement “within ninety (90) days following the Effective Date” is hereby deleted and replaced with

“within one hundred twenty (120) days after the date of receipt by SBEV of the Data Package”.

8. Consent

to Collaboration and Sublicense. RGT hereby acknowledges that SBEV intends to enter into the Collaboration Agreement with Lupvindol

UK Limited (“Lupvindol”) for the purpose of advancing the Licensed Product as an Investigational Veterinary

Product through the FDA Center for Veterinary Medicine INAD and Conditional Approval pathway. In furtherance thereof, and pursuant to

Section 2.3 of the Agreement, RGT hereby consents to SBEV granting to Lupvindol a non-exclusive, non-transferable, non-sublicensable,

royalty-free license during the term of the Collaboration Agreement to use, access, and reference the Intellectual Property solely within

the Veterinary Field and the Territory, and solely to the extent necessary for Lupvindol to perform its obligations under the Collaboration

Agreement. Such consent shall not relieve SBEV of any of its obligations under the Agreement, and SBEV shall remain primarily responsible

for all obligations thereunder. RGT’s consent to the foregoing sublicense shall not be construed as consent to any other sublicense

or grant of rights to any other third party.

9. Full

Force and Effect. Except as expressly amended by this Addendum, the Agreement remains in full force and effect and is hereby ratified

and confirmed.

10. Counterparts.

This Addendum may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one

and the same instrument.

11. Governing

Law. This Addendum shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its

conflict of laws principles.

[Signature Page Follows]

IN WITNESS WHEREOF, the Parties have executed

this Addendum as of the Addendum Effective Date.

ARGENT BIOPHARMA LIMITED

By:

/s/ Roby Zomer

Name: Roby Zomer

Title: Chairman

SPLASH BEVERAGE GROUP, INC.

By:

/s/ Brady Cobb

Name: Brady Cobb

Title: Interim CEO

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7811_ex99-1.htm · Sequence: 3

EXHIBIT 99.1

Splash Beverage Group Expands CannEpil® Platform

into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Expansion broadens CannEpil into veterinary therapeutics

as Splash advances its cannabinoid pharmaceutical development platform

FORT LAUDERDALE, Fla., July 29, 2026—

Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has expanded

its exclusive global license for CannEpil® to include veterinary therapeutic applications, creating a second regulated pharmaceutical

development platform alongside the Company’s existing human pharmaceutical program.

The expanded field of use grants Splash exclusive

worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions.

CannEpil is a proprietary pharmaceutical-grade cannabinoid

formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates formulated in an oral liquid solution and manufactured

under European Union Good Manufacturing Practice (EU-GMP) standards. Originally developed as a potential treatment for drug-resistant

epilepsy, CannEpil has previously been supplied through physician-directed access programs in international markets and has been assigned

an Investigational New Drug (IND) application number by the U.S. Food and Drug Administration for its human development program.

Splash intends to initially evaluate CannEpil for

veterinary applications in companion-animal oncology and chronic pain management, with canine indications expected to represent the initial

development focus. The Company intends to pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine’s Investigational

New Animal Drug (INAD) and Conditional Approval pathways.

Addressing Significant and Growing Companion-Animal

Markets

The Company’s veterinary expansion positions

CannEpil within two significant and growing areas of companion-animal medicine.

According to Grand View Research, the global veterinary

pain management market was valued at approximately $2.6 billion in 2024 and is projected to reach approximately $3.8 billion

by 2030, driven by increasing pet ownership, longer lifespans and growing demand for advanced veterinary care.

Companion-animal oncology represents another meaningful

opportunity. Independent industry estimates place the global veterinary oncology market between approximately $900 million and $1.7

billion, depending on the products and services included, with continued long-term growth expected.

The underlying patient population is substantial.

According to the Veterinary Cancer Society, one in four dogs will develop cancer during their lifetime, while approximately half

of dogs over the age of ten will develop cancer. The U.S. National Cancer Institute estimates that approximately six million dogs are

diagnosed with cancer each year in the United States.

“Expanding our exclusive CannEpil license

into veterinary medicine materially broadens the value of the platform and provides access to significant companion-animal oncology and

pain-management markets,” said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group. “Cancer and chronic

pain affect millions of companion animals, yet treatment options remain limited in many indications. We believe CannEpil’s pharmaceutical-grade

formulation warrants disciplined evaluation through the FDA veterinary process.”

Under the amendment, Splash will pay Argent BioPharma

Limited a 10% royalty on net revenues generated from veterinary applications of CannEpil.

The Company is also finalizing a strategic joint

venture with an established cannabinoid pharmaceutical company to lead CannEpil’s veterinary development program. The partner’s

executive leadership includes experienced pharmaceutical development professionals with a demonstrated track record of advancing cannabinoid-based

medicines through regulatory approval and commercialization. Splash expects to announce additional details regarding the collaboration

in the near future.

Executing a Diversified Cannabinoid Health Sciences

Strategy

“Our objective extends well beyond expanding

the licensed field of use,” Cobb continued. “We are assembling a world-class development platform around CannEpil by

partnering with experienced cannabinoid pharmaceutical executives who have successfully navigated complex regulatory pathways and helped

bring cannabinoid medicines to market. We believe pairing differentiated intellectual property with proven scientific and regulatory expertise

materially enhances our ability to create long-term shareholder value.”

“Splash is executing a disciplined strategy

to build a diversified cannabinoid health sciences platform by commercializing existing international pharmaceutical assets, advancing

FDA-regulated veterinary and human therapeutics, and developing innovative cannabinoid consumer wellness and beverage brands for global

markets. The expansion of CannEpil into veterinary medicine represents another important milestone in executing that strategy and further

positions Splash at the intersection of pharmaceutical innovation and cannabinoid science.”

The Company believes the expanded veterinary rights

complement its broader strategy of commercializing pharmaceutical cannabinoid assets across multiple regulated healthcare markets. Actual

development timelines, target indications, clinical requirements and regulatory pathways will be determined following engagement with

the FDA and other applicable regulatory authorities.

There can be no assurance that CannEpil will receive

Conditional Approval, full approval or any other regulatory authorization for veterinary use, or that any commercialization efforts will

be successful.

About CannEpil®

CannEpil® is a proprietary pharmaceutical-grade

cannabinoid formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates formulated in an oral liquid solution

and manufactured under European Union Good Manufacturing Practice (EU-GMP) standards. Originally developed for drug-resistant epilepsy,

CannEpil has previously been supplied through physician-directed access pathways in select international markets and is being advanced

for additional pharmaceutical indications.

About Splash Beverage Group, Inc.

Splash Beverage Group, Inc. (NYSE American: SBEV)

is a publicly traded company headquartered in Fort Lauderdale, Florida. The Company is pursuing a strategic transformation toward becoming

a cannabinoid health, wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions,

and other platform-building initiatives.

More Information

Splash Beverage Group

Contact Information

Splash Beverage Group

Info@SplashBeverageGroup.com

Media Contact

Angela Gorman

AMWPR

angela@amwpr.com

917-348-0083

Forward-Looking Statements

This press release contains forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements

regarding the Company’s plans to develop and commercialize CannEpil for veterinary applications; anticipated regulatory pathways,

including the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD) and Conditional Approval processes; estimates

and projections for the market for veterinary treatments including oncology and pain management uses, the completion of a proposed joint

venture; the anticipated capabilities and experience of prospective development partners; the commercialization of international pharmaceutical

assets; the development of additional cannabinoid therapeutics, wellness and beverage products; and the Company’s broader strategic

initiatives including its strtagy of commercializing pharmaceutical cannabinoid assets across multiple regulated healthcare markets. Forward-looking

statements are prefaced by words such as “anticipate,” “expect,” “plan,” “could,” “may,”

“will,” “should,” “would,” “intend,” “potential,” “believe,” “estimate,”

“forecast,” “project,” and similar words.

Forward-looking statements are based on current expectations

and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially. Actual results

may differ materially from those contemplated by such forward-looking statements due to a variety of risks and uncertainties which include,

among others, the possibility that the license and our efforts to develop and commercialize the licensed product do not yield the benefits

anticipated or sought, the risk that we and the licensor are not able to obtain, maintain or protect intellectual property rights in the

licensed product in jurisdictions in which we seek to develop and commercialize the product and that competitors market the same or similar

products, our ability to negotiate ad execute a joint venture with a strategic collaborator to assist in our planned efforts in the veterinary

treatment space, our need to comply with contractual obligations to maintain our rights and develop and commercialize the licensed product,

our ability to raise the capital necessary to develop and commercialize the product and otherwise meet our working capital needs, our

need to comply with extensive regulations including clinical testing before we can market the product in applicable jurisdictions including

the U.S., our ability to recommence revenue generating activities with our limited staffing, and the status of evolving regulatory conditions

within the cannabinoid and wellness industries, and our ability to regain and maintain compliance with American listing standards. There

can be no assurance that CannEpil will receive regulatory approval for any indication or that any development or commercialization initiative

will achieve its intended results.

Additional information concerning these and other

risk factors is contained in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report

on Form 10-K for the year ended December 31, 2025 and the Final Prospectus on Form 424B3 filed on June 26, 2026. Any forward-looking statement

made by the Company speaks only as of the date on which it is made.

Readers are cautioned not to place undue reliance

on these forward-looking statements, which speak only as of the date made. Splash undertakes no obligation to update any forward-looking

statements, whether as a result of new information, future developments, or otherwise, except as required by applicable law.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jul. 28, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 28, 2026

Entity File Number

001-40471

Entity Registrant Name

SPLASH BEVERAGE GROUP, INC.

Entity Central Index Key

0001553788

Entity Tax Identification Number

34-1720075

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1112 N. Flagler Drive

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33304

City Area Code

(954)

Local Phone Number

648-7238

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

SBEV

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration